J2281
HCPCSInj moxifloxacin (fres kabi)
Official HCPCS Level II long descriptor
Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg
HCPCS Level II code J2281 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Inj moxifloxacin (fres kabi)
Added to HCPCS: 2023-01-01
Nearby codes in J2
- J2265Minocycline hydrochloride
- J2267Inj, mirikizumab-mrkz, 1 mg
- J2270Morphine sulfate injection
- J2272Inj, morphine (fresenius)
- J2274Inj morphine pf epid ithc
- J2277Inj, motixafortide, 0.25 mg
- J2278Ziconotide injection
- J2280Inj, moxifloxacin 100 mg
- J2290Inj, nafcillin sodium, 20 mg
- J2291Inj, nafcillin (baxter) 20mg
- J2300Inj nalbuphine hydrochloride
- J2305Inj, nitroglycerin, 5 mg
- J2312Inj naloxone hcl nos, 0.01mg
- J2313Inj, naloxone (zimhi) 0.01mg
- J2315Naltrexone, depot form
- J2320Nandrolone decanoate 50 mg
Where this code sits
Krasyn AI Coder
Get code suggestions automatically as you type notes. Free for 50 analyses.
Install for Chrome — freeSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.